Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Accured Expenses (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Change in Accured Expenses for 13 consecutive years, with -$1.3 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 142.63% to -$1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, up 173.09% year-over-year, with the annual reading at $4.0 million for FY2025, 173.09% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$1.3 million at Theravance Biopharma, down from $3.6 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $9.9 million in Q3 2022, with the low at -$36.5 million in Q3 2021.
  • Average Change in Accured Expenses over 5 years is -$2.1 million, with a median of -$652000.0 recorded in 2021.
  • The sharpest move saw Change in Accured Expenses crashed 754.69% in 2021, then skyrocketed 782.88% in 2024.
  • Over 5 years, Change in Accured Expenses stood at -$652000.0 in 2021, then soared by 1616.72% to $9.9 million in 2022, then plummeted by 104.43% to -$438000.0 in 2023, then surged by 782.88% to $3.0 million in 2024, then tumbled by 142.63% to -$1.3 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$1.3 million, $3.6 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.